News | Patient Positioning Radiation Therapy | July 19, 2019

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories

Global revenues for radiotherapy patient positioning devices to exceed $500 million in 2019

Stronger Distribution Networks to Bolster Radiotherapy Patient Positioning Accessories

July 17, 2019 — A recent study projects global market revenues for radiotherapy patient positioning accessories will exceed revenues of $500 million in 2019. This represents a moderate 4.3 percent annual growth over 2018, with nearly 1/5 of the overall installed base of radiotherapy patient positioning accessories accounted for by couch tops and overlays, followed by immobilization systems.

More than 40 percent of the total adoption of radiotherapy patient positioning accessories is registered by hospitals at a global level, as indicated by the report from Future Market Insights. A higher rate of demand for radiotherapy patient positioning accessories is likely to be recorded by cancer research institutes and radiation therapy/proton therapy centers in the forthcoming years.

Government Support Pivotal in Accelerating Installation of Radiotherapy Patient Positioning Accessories

North America and Europe currently hold a combined revenue share of more than 60 percent in the global radiotherapy patient positioning accessories market. A remarkable increase in the rate of early cancer diagnosis is leading to a hike in the adoption of radiotherapy, more prominently in developed countries such as the U.S., U.K. and Germany among others, according to the FMI report. Moreover, the study opines that the increasing awareness about multiple types of cancers, further backed by favorable government initiatives regarding cancer diagnosis and treatment, will be one of the strongest factors pushing penetration of radiotherapy patient positioning accessories within developed regional markets.

On the other side, governments of several developing economies are also extending support and investments in the cancer diagnosis and treatment space, particularly through screening camps, which is boosting the diagnosis rates of cancer. This according to the report is majorly responsible for promising growth in the installed base of radiotherapy systems and patient positioning accessories. According to analysis, the flourishing medical tourism sector is also registering significant contribution to the thriving demand for radiotherapy patient positioning accessories in emerging economies.

Strategic Efforts in Stronger Distribution Network Gathering Momentum Among Manufacturers

Some of the key players actively competing in the radiotherapy patient positioning accessories market include Bionix Radiation Therapy, CDR Systems, Civco Radiation, Orfit Industries N.V., IZI Medical Products, Klarity Medical Products, Qfix, Elekta AB, and Eckert & Ziegler BEBIG, among others. Several leading manufacturers are focused on the development and approval of new products. For example, Civco Radiotherapy announced U.S. Food and Drug Administration (FDA) clearance and CE mark for their Solstice SRS (stereotactic radiosurgery) Immobilization System, in the second half of 2018.

Strong distribution partnerships tend to result in effective product reach across the value chain and thereby support the business growth. While the growing trend of strategic distribution partnerships between peer companies operating in the radiotherapy patient positioning accessories market is translating into improved product outreach, the analysis suggests that collaborative activities will particularly benefit smaller players in the market. Recently, Poll Medical entered a partnership with Civco for the global distribution of Poll’s CE-marked GrayDuck Stents, a new custom oral stent to provide immobilization and tissue sparing of the tongue during head and neck radiotherapy. 

Access the full FMI report here.

For more information: www.futuremarketinsights.com

Related Content

Sponsored Content | Videos | Proton Therapy | December 16, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a peek at the history of machine learning/AI in
In connection with the collaboration, Elekta has committed to make an investment in ViewRay representing approximately 9.9 percent of the shares of ViewRay’s common stock
News | Radiation Therapy | December 13, 2019
December 13, 2019 — Elekta announced that the company has sign
UFHPTI expands its proton therapy capacity and treatment range with the Proteous One
News | Radiation Therapy | December 12, 2019
December 12, 2019 — IBA (Ion Beam Applications SA) announced that

Image courtesy of Elekta 

News | Radiation Therapy | December 11, 2019
December 11, 2019 — A new clinical guideline from the American Soci...
RaySearch Laboratories AB (publ) has experienced strong growth in recent years, creating the need for larger and more efficient premises
News | Radiation Therapy | December 09, 2019
December 9, 2019 — Karin Gedda, architect and i